XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.3
EARNINGS PER SHARE
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
The numerator for both basic and diluted earnings per share (EPS) is net income (loss) attributable to Baxter stockholders. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, RSUs and PSUs is reflected in the denominator for diluted EPS using the treasury stock method.
The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.
Three Months Ended September 30,Nine Months Ended September 30,
(in millions)2024202320242023
Income (loss) from continuing operations$61 $37 $162 $(38)
Less: Net income attributable to noncontrolling interests included in continuing operations— — — — 
Income (loss) from continuing operations attributable to Baxter stockholders61 37 162 (38)
Income (loss) from discontinued operations83 2,474 (290)2,455 
Less: Net income attributable to noncontrolling interests included in discontinued operations4 3 9 6 
Income (loss) from discontinued operations attributable to Baxter stockholders79 2,471 (299)2,449 
Net income (loss) attributable to Baxter stockholders$140 $2,508 $(137)$2,411 

The following table is a reconciliation of basic shares and diluted shares.
Three Months Ended September 30,Nine Months Ended September 30,
(in millions)2024202320242023
Basic shares510 507 509 506 
Effect of dilutive securities2 2 2 — 
Diluted shares512 509 511 506 
Basic and diluted shares are the same for nine months ended September 30, 2023 due to our loss from continuing operations attributable to Baxter stockholders. The effect of dilutive securities includes unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excludes 18 million and 19 million shares issuable under equity awards for the three and nine months ended September 30, 2024, and 18 million and 25 million shares issuable under equity awards for the three and nine months ended September 30, 2023, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS.